May 22, 2020
The use of investigational drugs during a public health crisis is not new. In 2014, Dr. Linda Mobula had experience administering an untested drug during the Ebola response in West Africa. Mobula talks to Dr. Josh Sharfstein about how the technical framework that came out of that process could have been used to provide guidance for investigational drugs in COVID-19, and how political figures created a global push for hydroxychloroquine.